We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026
20 Aug 2026 - 22 Aug 2026

Blocking Copper Function Prevents Restenosis in Arteries

By HospiMedica staff writers
Posted on 19 Jun 2003
Scientists have discovered that the renarrowing of arteries following balloon angioplasty can be halted by copper chelation therapy. More...
Their discovery was reported in the May 27, 2003, issue of the Proceedings of the (US) National Academy of Sciences.

The investigators found that the function of copper is necessary for restenosis, and after angioplasty or stent surgery is performed, the presence of copper cells in artery cells enables the cells to regrow from within the injured vessel. In about 30% of cases, this process reclogs the artery, requiring more surgery. Preventing the function of copper in the body stops the artery from reclogging after angioplasty. The therapy works by limiting the cellular export of growth factors and cytokines involved in this process.

The commonly available reagent TTM (tetrathiomolybdate), which is a specific copper chelator, stopped inflammation and growth of the unwanted new tissue responsible for narrowing the arteries. TTM was able to inhibit the intracellular function of key regulators of cell growth, which normally enable cells to respond to stress.

"This represents a major contribution to medical science,” said Kenneth A. Ault, M.D., director of the Maine Medical Research Institute (MMCRI, Scarborough, USA; www.mmri.org). "This finding could be ready for widespread clinical use in humans in a very few years.”

The research was conducted by a team of scientists from Maine Medical Research Institute (Scarborough, USA) and a team from Dartmouth Hitchcock Medical Center (Lebanon, NH, USA). The discovery is the result of around 15 years of scientific research, said the participants.


Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Radiofrequency Generator
GX1
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.